Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
P/E ratio for Relmada Therapeutics, Inc. (RLMD)
P/E ratio as of 2023: -1.26
According to Relmada Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.26. At the end of 2022 the company had a P/E ratio of -0.66.
P/E ratio history for Relmada Therapeutics, Inc. from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.26 |
| 2022 | -0.66 |
| 2021 | -3.14 |
| 2020 | -8.41 |
| 2019 | -23.99 |
| 2018 | -2.65 |
| 2017 | -1.41 |
| 2016 | -1.57 |
| 2015 | -8.89 |
| 2014 | -4.85 |
| 2013 | -1266.24 |
| 2012 | -7094.26 |